Seven emerging AI healthcare technologies have been selected to move into the next phase of the MHRA’s AI Airlock programme, with pleasing number of diagnostic tools chosen.
The cohort includes tools aimed at dramatically reducing waiting times for tests, such as shrinking a bowel cancer screening process from weeks to minutes, and detecting conditions such as skin cancer, genetic eye disease, and interpreting blood tests faster.
In this controlled regulatory sandbox, the selected innovations will be trialled to ensure they deliver reliable results, identify any limitations, and pave the way toward regulatory approval. The initiative supports clinicians in making timely and informed decisions by embedding AI into pathways.
With diagnostics being a critical part of the care pathway — where earlier detection can significantly improve outcomes — the AI Airlock programme should help to aid their integration.
